On Nov. 23, 2020, Bellerophon Therapeutics announced that the independent Data Monitoring Committee (DMC) had completed its pre-specified interim analysis from the first 100 patients randomized in the Phase 3 COViNOX study of INOpulseﾮ for the treatment of COVID-19.

The interim analysis, as requested by the FDA, was limited to the evaluation of safety and a single efficacy endpoint of respiratory failure or death.